AtaiBeckley Inc. is a clinical-stage pharmaceutical company focused on developing treatments for mental health conditions, including depression, anxiety disorders, and cognitive impairment. The company's pipeline consists of multiple candidates in various stages of testing, featuring novel compounds such as intranasal mebufotenin for treatment-resistant depression, psychedelic-based therapies, and oral formulations targeting conditions with limited existing treatment options. Founded in 2018 with operations in the United States, Germany, and Canada, the company operates as a subsidiary of Eli Lilly and Company.

entry readiness 7 · NOT READY · exit proximity 35

Value area 4.86–7.45 · 8% of 119d volume overhead · clean runway